Embera is developing a patented drug combination to address 2 significant unmet medical needs smoking and cocaine dependence. Embera is advancing EMB-001 for smoking cessation ($1.9B WW market), based on positive animal study results where EMB-001 compared very favorably to Chantix®, Pfizer’s $638M smoking cessation drug. Embera is also developing the cocaine dependence indication for EMB-001 a $400M product opportunity leveraging grant funding.